Literature DB >> 32642933

Radiosurgery vs. microsurgery for newly diagnosed, small petroclival meningiomas with trigeminal neuralgia.

Hun Ho Park1, Woo Hyun Kim1, Hyun-Ho Jung2,3,4,5, Jong Hee Chang2,3,4,5, Kyu-Sung Lee1, Won Seok Chang6,7,8,9, Chang-Ki Hong10.   

Abstract

Trigeminal neuralgia (TN) is an excruciating pain that can occur with petroclival meningiomas (PCMs). Gamma knife radiosurgery (GKRS) is an appealing option for small PCMs, but the role of microsurgery (MS) compared to GKRS is not well defined for small PCMs with regard to TN relief. From January 2009 to September 2019, 70 consecutive patients were treated by GKRS or MS for newly diagnosed, small (< 3.5 cm) PCMs with TN. GKRS or MS were performed for 35 patients each. The surgical outcome and TN control according to Barrow Neurological Institute (BNI) score were retrospectively analyzed and compared between GKRS and MS. The predominant origin of PCMs was upper clival (49%) with trigeminal nerve compression at the medial dorsal root entry zone. Tumor control rates were equally 94% with GKRS or MS for a mean tumor size and volume of 2.3 cm and 5.3 cm3, respectively. The preoperative BNI scores were mostly II (40%) and IV (37%) with GKRS and MS, respectively. TN relief without medications (BNI scores I and II) was achieved in 13 of 35 patients (37%) with GKRS and 32 of 35 patients (91%) with MS during a mean follow-up of 50.5 months. The most common complications after GKRS and MS were dysesthesia (23%) and diplopia (9%), respectively. MS could be more effective than GKRS in providing prompt, medication-free pain relief from TN for small PCMs. The risks of MS have to be considered carefully in experienced hands, especially for small PCMs.

Entities:  

Keywords:  Gamma knife radiosurgery; Microsurgery; Skull base surgery; Small petroclival meningioma; Trigeminal neuralgia

Mesh:

Year:  2020        PMID: 32642933     DOI: 10.1007/s10143-020-01346-8

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  35 in total

1.  Motor cortex stimulation: functional magnetic resonance imaging-localized treatment for three sources of intractable facial pain.

Authors:  Darian R Esfahani; Marc T Pisansky; Rima M Dafer; Douglas E Anderson
Journal:  J Neurosurg       Date:  2010-05-28       Impact factor: 5.115

2.  Petrosal approach for petroclival meningiomas.

Authors:  O Al-Mefty; J L Fox; R R Smith
Journal:  Neurosurgery       Date:  1988-03       Impact factor: 4.654

3.  Long-term outcome after operation for trigeminal neuralgia in patients with posterior fossa tumors.

Authors:  F G Barker; P J Jannetta; R P Babu; S Pomonis; D J Bissonette; H D Jho
Journal:  J Neurosurg       Date:  1996-05       Impact factor: 5.115

4.  Intracranial tumors in patients with facial pain.

Authors:  E Bullitt; J M Tew; J Boyd
Journal:  J Neurosurg       Date:  1986-06       Impact factor: 5.115

5.  Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors.

Authors:  T M Cheng; T L Cascino; B M Onofrio
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

6.  Management of Recurrent Trigeminal Neuralgia Associated with Petroclival Meningioma.

Authors:  Shyamal C Bir; Tanmoy Kumar Maiti; Papireddy Bollam; Anil Nanda
Journal:  J Neurol Surg B Skull Base       Date:  2015-08-03

7.  Microsurgical removal of petroclival meningiomas: a report of 33 patients.

Authors:  A P Bricolo; S Turazzi; A Talacchi; L Cristofori
Journal:  Neurosurgery       Date:  1992-11       Impact factor: 4.654

8.  Percutaneous retrogasserian glycerol rhizotomy for trigeminal neuralgia. A prospective study of 100 cases.

Authors:  M J Arias
Journal:  J Neurosurg       Date:  1986-07       Impact factor: 5.115

Review 9.  A new classification for facial pain.

Authors:  Kim J Burchiel
Journal:  Neurosurgery       Date:  2003-11       Impact factor: 4.654

10.  Petroclival meningiomas: surgical experience in 109 cases.

Authors:  W T Couldwell; T Fukushima; S L Giannotta; M H Weiss
Journal:  J Neurosurg       Date:  1996-01       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.